M. Stoeckle

Discipline

Psychologie (3) Sociologie (1) Economies et finances (1) Anthropologie biologique (1)

Type de document

Articles (25) Colloques et conférences (1)

Co-auteur

Date

Source

Mot-clé

Human beings (19) Treatment (17) cohorte (17) thérapie (15) Therapeutics (15) Swiss (14) Older people (13) analyse (12) Patients (12) Analysis (12) Patients (12) temps (durée) (11) Time (11) Persons (11) Population (10) Population (10) infection (9) Infection (9) risque (7) âge (7) Risk (7) Impact (7) Age (7) Age (7) puits (6) adulte (6) Aging (6) Ci (Chinese poetry) (6) Sex (6) RNA (6)

Documents écrit par M. Stoeckle (26) | parle de M. Stoeckle (0)

Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohort.
F. Hovaguimian et al.
Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
L. Baumann et al.
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
P. Thoueille et al. (29 juil. 2022)
Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort study.
B.L. Winter et al. (20 juin 2022)
Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection.
F. Hovaguimian et al.
Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS).
A. Hachfeld et al.
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV.
J. Damas et al. (1 déc. 2021)
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
P. Courlet et al.
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
S. Alves Saldanha et al.
Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19
C. Marzolini et al.
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland.
KEA Darling et al. (2021)
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
D. Sculier et al.
HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection.
L.A. Carlisle et al. (31 oct. 2020)
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
P. Courlet et al.
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
C. Marzolini et al. (2020)
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
F. Stader et al. (2020)
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile.
I. Locatelli et al.
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV.
P. Courlet et al.
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.
F. Olearo et al.
Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland.
GMA Santos et al.
Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study.
L. Salazar-Vizcaya et al.
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
C. Béguelin et al.
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
P. Bruggmann et al. (2017)
Frequency of and Risk Factors for Depression among Participants in the Swiss HIV Cohort Study (SHCS).
A. Anagnostopoulos et al. (2015)
Loss to follow-up of HIV-infected women after delivery : The Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort Study
K. Aebi-Popp et al. (2014)

next